An anti-TNFR1 scFv-HSA fusion protein as selective antagonist of TNF action

Protein Engineering, Design and Selection

Volumn 26, Issue 10, 2013, Pages 581-587

  Berger, Verena ^a   Richter, Fabian ^b   Zettlitz, Kirstin ^b,d   Unverdorben, Felix ^b   Scheurich, Peter ^b   Herrmann, Andreas ^a,c   Pfizenmaier, Klaus ^b   Kontermann, Roland E ^b  

^a Celonic GmbH   (Germany)

^b UNIVERSITY OF STUTTGART   (Germany)

^c Baliopharm   (Switzerland)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

antagonist; human serum albumin; single chain Fv; tumor necrosis factor; tumor necrosis factor receptor 1

Indexed keywords

ANTAGONIST; HUMAN SERUM ALBUMINS; SINGLE-CHAIN FV; TUMOR NECROSIS FACTOR RECEPTORS; TUMOR NECROSIS FACTORS;

AFFINITY CHROMATOGRAPHY; ANTIBODIES; CELL CULTURE; GLYCOPROTEINS; SIGNAL TRANSDUCTION;

MACROPHAGES;

ATROSAB; HUMAN SERUM ALBUMIN; HYBRID PROTEIN; IMMUNOGLOBULIN G; IZI 061; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY HUMAN SERUM ALBUMIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; CROSS LINKING; DRUG HALF LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUARTZ CRYSTAL MICROBALANCE; SIGNAL TRANSDUCTION; STABLE TRANSFECTION;

ANTAGONIST; HUMAN SERUM ALBUMIN; SINGLE-CHAIN FV; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; HUMANS; MICE; PROTEIN ENGINEERING; PROTEIN STABILITY; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECOMBINANT FUSION PROTEINS; SERUM ALBUMIN; SIGNAL TRANSDUCTION; SINGLE-CHAIN ANTIBODIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84884990590     PISSN: 17410126     EISSN: 17410134     Source Type: Journal    
DOI: 10.1093/protein/gzt044     Document Type: Article

References (39)

1. Aggarwal, B. (2003) Nat. Rev. Immunol., 3, 745-756.
2. Beutler, B. and Cerami, A. (1986) Nature, 320, 584-588.
3. Black, R.A., Rauch, C.T., Kozlosky, C.T., et al. (1997) Nature, 385, 729-733.
4. Bongartz, T., Sutton, A.J., Sweeting, M.J., Buchan, I., Matteson, E.L. and Montori, V. (2006) JAMA, 295, 2275-2285.
5. Cabal-Hierro, L. and Lazo, P.S. (2012) Cell Signal., 24, 1297-1305.
6. Fontaine, V., Mohand-Said, S., Hanoteau, N., Fuchs, C., Pfizenmaier, K. and Eisel, U. (2002) J. Neurosci., 22, RC216(1-7).
7. Gannes, G.C., De Ghoreishi, M., Pope, J, Russell, A, Bell, D, Adams, S, Shojania, K, Martinka, M and Dutz, J.P. (2007) Arch. Dermatol., 143, 223-231.
8. Gardam, M.A., Keystone, E.C., Menzies, R, Manners, S, Skamene, E, Long, R and Vinh, D.C. (2003) Lancet Infect. Dis., 3, 148-155.
9. Goukassian, D.A., Qin, G., Dolan, C., et al. (2007) Circulation, 115, 752-762.
10. Grell, M., Douni, E., Wajant, H., et al. (1995) Cell, 83, 793-802.
11. Grell, M., Wajant, H., Zimmermann, G and Scheurlich, P. (1998) Proc. Natl Acad. Sci. USA, 95, 570-575.
12. Greulich, B., Poppe, M., Woischnig, H, Landauer, K and Herrmann, A. (2011) BMC Proc., 5(Suppl 8):P40.
13. Jefferis, R. (2007) Expert Opin. Biol. Ther., 7, 1401-1413.
14. Kishore, R., Tkebuchava, T., Sasi, S.P, Silver, M, Gilbert, H.Y, Yoon, Y.S, Park, H.Y, Thorne, T, Losordo, D.W and Goukassian, D.A. (2011) Adv. Exp. Med. Biol., 691, 433-448.
15. Kleinbongard, P., Heusch, G. and Schulz, R. (2010) Pharmacol. Ther., 127, 295-314.
16. Kontermann, R.E. (2009) Bio. Drugs, 23, 93-109.
17. Kontermann, R.E. (2011) Curr. Opin. Biotechnol., 22, 868-876.
18. Kontermann, R.E., Martineau, P., Cummings, C.E, Karpas, A, Allen, D, Derbyshire, E andWinter, G. (1997) Immunotechnology, 3, 137-144.
19. Kontermann, R.E., Munkel, S., Neumeyer, J, Muller, D, Branschadel, M, Scheurich, P and Pfizenmaier, K. (2008) J. Immunother., 31, 225-234.
20. Kontermann, R.E., Scheurich, P. and Pfizenmaier, K. (2009) Expert Opin. Drug Discov., 4, 279-292.
21. Kratz, F. and Elsadek, B. (2012) J. Control. Release, 161, 429-445.
22. Krippner-Heidenreich, A., Tubing, F., Bryde, S, Willi, S, Zimmermann, G and Scheurich, P. (2002) J. Biol. Chem., 277, 44155-44163.
23. Lencer, W.I. and Blumberg, R.S. (2005) Trends Cell Biol., 15, 5-9.
24. Levick, J.R. (1981) Arthritis Rheumat., 24, 1550-1560.
25. Lewis, A.K., Valley, C.C. and Sachs, J.N. (2012) Biochemistry, 551, 6546-6555.
26. Liu, M., Huang, Y., Hu, L, Liu, G, Hu, X, Liu, D and Yang, X. (2012) BMC Biotechnol., 12, 68.
27. Locksley, R.M., Killeen, L.M. and Leonardo, M.J. (2001) Cell, 104, 487-501.
28. Loetscher, H., Gentz, R., Zulauf, M, Lustig, A, Tabuchi, H, Schlaeger, E.J, Brockhaus, M, Gallati, H, Manneberg, M and Lesslauer, W. (1991) J. Biol. Chem., 266, 18324-18429.
29. Muller, D., Karle, A., Meissburger, B, Hofig, I, Stork, R and Kontermann, R.E. (2007) J. Biol. Chem., 282, 12650-12660.
30. Palframan, R., Airey, M., Moore, A, Vugler, A and Nesbitt, A. (2009) J. Immunol. Methods, 348, 36-41.
31. Ramos-Casals, M., Brito-Zerón, P., Soto, M.J, Cuadrado, M.J and Khamashta, M.A. (2008) Best Pract. Res. Clin. Rheumatol., 22, 847-861.
32. Richter, F., Liebig, T., Guenzi, E, Herrmann, A, Scheurich, P, Pfizenmaier, K and Kontermann, R.E. (2013) PLOS ONE, 8, e72156.
33. Robak, T., Gladalska, A. and Stepien, H. (1998) Eur. Cytokine Netw., 9, 145-154.
34. Scott, D.L. (2012) Clin. Pharmacol. Ther., 91, 30-43.
35. Smith, R.A. and Baglioni, C. (1987) J. Biol. Chem., 262, 6951-6954.
36. Van Liederkerke, B.M., Nelis, H.J., Kint, J.A, Vanneste, F.W and De Leenheer, A.P. (1991) J. Pharm. Sci., 80, 11-16.
37. Wajant, H., Pfizenmaier, K. and Scheurich, P. (2003) Cell Death Differ., 10, 45-65.
38. Wunder, A., Muller-Ladner, U., Stelzer, E.H.K, Funk, J, Neumann, E, Stehle, G, Pap, T, Sinn, H, Gay, S and Fiehn, C. (2003) J. Immunol., 170, 4793-4801.
39. Zettlitz, K.A., Lorenz, V., Landauer, K, Munkel, S, Herrmann, A, Scheurich, P, Pfizenmaier, K and Kontermann, R. (2010) MAbs, 2, 639-647.